MorphoSys hocks royalties to buy Constellation Pharma

3 June 2021

Shares of US cancer drug maker Constellation Pharmaceuticals (Nasdaq: CNST) closed up a massive 66.7% at $33.74 yesterday on the news that it has agreed to be acquired by Germany’s MorphoSys (FSE: MOR).

However, MorphoSys shares fell 13% to 63.02 euros because of the unusual funding arrangement, for what it called a “this transformational acquisition.”

MorphoSys is offering $34.00 per share in cash, which represents a total equity value of $1.7 billion. The transaction has been unanimously approved by the management board and the supervisory board of MorphoSys, as well as the board of directors of Constellation and is expected to close in the third quarter of 2021.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK